Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jun 14, 2014; 20(22): 6912-6917
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6912
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6912
Serum adipokines in inflammatory bowel disease
Marek Waluga, Marek Hartleb, Grzegorz Boryczka, Department of Gastroenterology and Hepatology, Medical University of Silesia, 40-752 Katowice, Poland
Michał Kukla, Krystyna Żwirska-Korczala, Department of Physiology Zabrze, Medical University of Silesia, 40-055 Katowice, Poland
Author contributions: Waluga M conceived the study, analyzed the data and drafted the manuscript; Hartleb M participated in the study design and helped prepare the manuscript; Boryczka G assisted with blood samples and data collection; Kukla M and Żwirska-Korczala K assisted with technical issues and statistical analysis; all authors read and approved the final version of the manuscript.
Supported by A grant from the Medical University of Silesia, No. KNW-1-119/P/1/0
Correspondence to: Marek Waluga, MD, PhD, Department of Gastroenterology and Hepatology, Medical University of Silesia, ul. Medyków 14, 40-752 Katowice, Poland. mwaluga@sum.edu.pl
Telephone: +48-32-7894401 Fax: +48-32-7894402
Received: December 12, 2013
Revised: February 18, 2014
Accepted: March 8, 2014
Published online: June 14, 2014
Revised: February 18, 2014
Accepted: March 8, 2014
Published online: June 14, 2014
Core Tip
Core tip: Recently, many adipokines with varying metabolic effects have been discovered. A bidirectional interaction between inflammation of the gut and visceral fat may exist in cases of inflammatory bowel disease (IBD). In this work, plasma levels of selected adipokines were studied in subjects with Crohn’s disease and ulcerative colitis before treatment and after achieving clinical remission. The results of this study indicate that IBD modulates serum adipokine levels by stimulating resistin and visfatin release and suppressing leptin production.